The Science Layer

The scientific basis for young blood's rejuvenating effects traces to 1864, when physiologist Paul Bert first surgically conjoined two rodents to share circulation. Clive McCay at Cornell revived the approach in the 1950s, observing apparent longevity benefits in older mice exposed to young blood. The modern era began in 2005, when Thomas Rando's group at Stanford, working with postdoctoral researchers Irina and Michael Conboy, published in Nature showing that young blood activated regenerative signaling pathways in the liver and muscle cells of old mice. The findings were replicated across multiple labs and extended across the brain, intestines, kidneys, and bones. The mechanism: circulating factors in young blood — proteins, exosomes, and other signals — activate molecular pathways that aging had silenced.

Key proteins identified: GDF11 (cardiac and skeletal muscle regeneration, though its role remains debated), oxytocin (neurogenesis and muscle repair), PEDF (pigment epithelium-derived factor, a recent candidate demonstrated to produce systemic rejuvenation in aged mice when administered alone), and CCL11 (a pro-aging signal that increases with age and impairs neurogenesis). The research from UC Berkeley's Conboy lab further demonstrated that diluting old plasma — replacing it with saline and albumin rather than young blood — produces equivalent or superior rejuvenation effects in some tissues, suggesting that removing inhibitory old-blood factors may be as important as adding young-blood factors. This finding complicates the commercial plasma transfusion model but does not undermine the fundamental science of circulating factor effects on aging.

Senescent cells are cells that have stopped dividing but resist death, accumulating with age and secreting inflammatory signals (the senescence-associated secretory phenotype, SASP) that damage surrounding tissues. In a landmark 2015 study, James Kirkland's group at Mayo Clinic demonstrated that a combination of dasatinib (a cancer drug) and quercetin (a plant flavonoid) selectively killed senescent cells in aged mice, reducing frailty, rejuvenating cardiac function, and improving running endurance. The finding launched the field of senolytics.

Human clinical translation has proceeded rapidly by biomedical standards. The first human senolytic trial treated patients with idiopathic pulmonary fibrosis and found improved physical function. A subsequent trial in diabetic kidney disease directly demonstrated for the first time that D+Q reduces senescent cells in humans. As of 2024, Mayo Clinic, Cedars-Sinai, and the Translational Geroscience Network are running nearly 90 active clinical trials. A December 2024 Cedars-Sinai pilot found that a six-week D+Q regimen significantly improved cognition in older adults with mild cognitive impairment. The field's pace has moved faster than James Kirkland, the discipline's pioneer, expected. Human benefits are coming into view.

In 2006, Shinya Yamanaka (Nobel Prize 2012) discovered that four transcription factors — now called Yamanaka factors — can reprogram adult cells to an embryonic-like state. The implications for aging were immediate: if the epigenetic marks that tell cells they are old could be reset, cells might function as young again. Juan Carlos Izpisúa Belmonte at the Salk Institute demonstrated in 2016 that applying Yamanaka factors to entire living mice produced signs of age reversal — at controlled doses, without the teratoma risk of full reprogramming. Partial reprogramming became the field's central concept.

Multiple labs have since demonstrated partial epigenetic reprogramming's rejuvenating effects in specific cell types and tissues: eye cells (Harvard's David Sinclair), muscle cells, and 20+ human cell types from aged donors (Vittorio Sebastiano at Stanford). Altos Labs was built specifically to advance this science, recruiting Yamanaka himself along with a roster of Nobel laureates and the world's leading aging biologists. The company's 2025 appointment of a Chief Medical Officer signals the transition from basic research toward human trials. The epigenetic clock — Steve Horvath's tool for measuring biological age in DNA methylation patterns — provides the measurement infrastructure for translating this research into interventions: if biological age can be measured precisely, the effect of any intervention can be assessed without waiting decades for mortality outcomes.